...Predictive Biomarker will use its technology to characterize the mechanism of action of Unibioscreen's UNBS1450. The...
...tumor cell lines' response to drugs through the use of fluorescent reporters observed in real-time. Unibioscreen...
...for further development. Financial terms were not disclosed. Predictive Biomarker Sciences Inc. , Mesa, Ariz. Unibioscreen S.A....

...26, 2009 Patent application filed; available for licensing from Unibioscreen S.A. Contact: Unibioscreen S.A., Brussels, Belgium e-mail: business@unibioscreen.com...

...a dose-escalation, European Phase I trial of intravenous UNBS1450 in patients with advanced solid tumors. Unibioscreen S.A....

...also is developing UBNS 5162, a pan-antagonist of CXCL chemokines it licensed in September from Unibioscreen S.A....

...received exclusive, worldwide rights from Unibioscreen to develop and commercialize UNBS 5162 for all indications. Unibioscreen...
...in Phase I testing to treat advanced solid tumors. Drais Pharmaceuticals Inc. , Bridgewater, N.J. Unibioscreen S.A....